Symbols

BNGO

Bionano Genomics·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 1

Revenue Beats Expectation

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About BNGO

Bionano Genomics, Inc.

A company that develops saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection

Industry

Life Science Tools and Services

Established Date

08/16/2007

Listing Date

09/21/2018

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.bionano.com

Security Type

Common stock

Office address

9540 Towne Centre Drive , Suite 100 , San Diego , CA 92121

Business

Introduction

Bionano Genomics, Inc., was incorporated in Delaware on August 16, 2007. The company is a provider of genome analysis solutions, including optical genome mapping systems, nucleic acid extraction and purification platforms, and data analysis software. Its products serve basic, translational and clinical research applications, as well as diagnostic testing services.

Company Financials

EPS

BNGO has released its 2025 Q4 earnings. EPS was reported at -0.77, versus the expected -0.45, missing expectations. The chart below visualizes how BNGO has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

BNGO has released its 2025 Q4 earnings report, with revenue of 7.95M, reflecting a YoY change of -2.60%, and net profit of -7.93M, showing a YoY change of 60.58%. The Sankey diagram below clearly presents BNGO's revenue sources and cost distribution.